Search PubMed⌕ Search

Biomedical subjects

T Maki

Publications and source records attributed to T Maki.

At least 253 records · Page 14Linked to original sources
PubMed1980

Effect of a single transfusion of donor-specific and nonspecific blood on skin allograft survival in mice.

The effect of a single transfusion of donor-specific or nonspecific blood on skin allograft survival was studied in ALS-treated mice. In the weak H-2-incompatible C3H/He to B6AF1 combination, transfusion of outbred CF1 blood induced significant prolongation of C3H/He skin graft survival when given over a wide interval of days between transfusion and skin grafting. In contrast, donor-specific C3H/He blood was effective only when given 10 days before grafting. Transfusion of either red blood cells or lymphocytes separated from CF1 or C3H/He whole blood also prolonged C3H/He skin graft survival. In the relatively strong H-2 incompatible DBA/2 to B6AF1 combination, significant prolongation of DBA/2 skin grafts was induced only by transfusion of donor-specific DBA/2- and H-2-compatible BALB/c blood. A single transfusion of C3H/He or CF1 blood failed to prolong DBA/2 skin graft survival. In the strong H-2-incompatible DBA/1 to B6AF1 combination, donor-specific DBA/1 blood was effective in prolonging DBA/1 skin graft survival. These results demonstrate that the effectiveness of donor-specific or nonspecific blood is dependent on (1) the degree of H-2 incompatibility of donor-recipient pairs and (2) timing of the blood transfusion relative to skin grafting.

Animals↗
PubMed1980

[Laboratory and clinical studies of cefamandole in pediatric infections (author's transl)].

Five patients with suppurative tonsillitis (1), urinary tract infection (1), staphylococcal impetigo (1), cervical lymphadenitis (1) and mycoplasma pneumonia were treated with cefamandole (CMD). CMD was administered by one shot intravenous or drip infusion at a dosage of 100 approximately 135 mg/kg/day for 4 approximately 14 days. Of 5 patients with those infections, excellent response was obtained in 3 patients, good response in 1 patient and unknown response in 1 patient. The overall efficacy rate was 100% except unknown response in mycoplasma pneumonia. In 3 of these 5 cases causative organisms were S. epidermidis, E. coli, and S. aureus, respectively. These organisms were all eliminated. No side effects were observed.

Age Factors↗
PubMed1978

[Clinical studies of PC 904 in pediatrics (author's transl)].

PC-904 was administered to 3 pediatric patients with serious infections resistant clinically to other antibiotics (2 cases of sepsis and 1 case of pseudomonal pneumonia). Daily dosage was 100 approximately 150 mg/kg and intravenous infusions were carried out in 2 or 3 divided doses. This drug showed clinically and bacteriologically good response in these patients without any side effect, and was considered to be a useful drug or worthwhile to use in the treatment of the serious infectious diseases such as sepsis or pseudomonal infections.

Age Factors↗
PubMed1978

[Basic and clinical studies on new semisynthetic penicillin, PC-904, in pediatric field (author's transl)].

PC-904 was administered to 16 pediatric patients and the following basic and clinical results were obtained. (1) PC-904 was administered 20 approximately 30 mg/kg. The serum peak level of PC-904 after drip intravenous infusion over 1 hour was 66.7 microgram/ml at 1 hour and T 1/2 of PC-904 was 67.8 minutes. PC-904 was administered 25 approximately 30 mg/kg intravenous one shot injection was 49.4 microgram/ml at 1 hour and T 1/2 of PC-904 was 52.2 minutes. (2) Urinary excretion rate was about 20% up to 6 hours after drip intravenous infusion of 20 mg/kg. In a case of intravenous one shot injection of 25 approximately 30 mg/kg, the excretion rate was 11.9 approximately 19.9%. (3) PC-904 was administered 60 approximately 120 mg/kg/day for 3 approximately 48 days to 5 cases of sepsis and bacterial endocarditis, 6 of pneumonia, 2 of sss syndrome (staphylococcal scald skin syndrome) and 3 of pyelonephritis. Clinical effects were excellent in 11 cases and good in 5 cases, effective ratio being 100%. (4) Pseudomonas aeruginosa, Staphylococcus epidermidis, Streptococcus viridans, Acinetobacter anitratus and Hemophilus influenzae isolated from clinical specimens disappeared by the treatment of PC-904, and Hemophilus influenzae isolated from clinical specimens disappeared by the treatment of PC-904. Escherichia coli and Klebsiella pneumoniae reduced. (5) As to the side effect by PC-904, s-GOT and s-GPT were elevated in 2 cases. Anemia, rash and fever were observed in each 1 case out of 16 patients though the causal relation with the agent was unknown.

Age Factors↗
PubMed1977

Pylorus-preserving procedure in partial and total gastrectomy.

1. The operative technique and the postoperative results of the original pylorus-preserving gastrectomy (PPG) and those of the Maki procedure as applied to cases of total gastrectomy are reported briefly. 2. The essence of these operations is to retain the pyloric cuff of 1.0-1.5 cm in length in order to preserve sphincteric function without the use of the drainage procedure. Ingested food was seen to empty gradually and rhythmically through the pyloric ring into the duodenum thereby avoiding dumping syndrome and reflux esophagitis. 3. As gastric acidity is reduced sufficiently by PPG, this method is to be recommended for treatment of intractable gastric ulcer cases and other benign lesions in which the foci are located in the distal half of the stomach. Though the method seems to be also useful in selected cases of duodenal ulcer, stenosis at the level of the pylorus and duodenum may preclude the application of the method. 4. The Maki procedure with jejunal interposition following nearly-total proximal gastrectomy is recommended in patients whose pylorus and its surroundings have remained free of tumor.

Dumping Syndrome↗